Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
17.64
-0.69 (-3.76%)
At close: Jan 26, 2026, 4:00 PM EST
17.64
0.00 (0.00%)
After-hours: Jan 26, 2026, 4:39 PM EST
Zai Lab Revenue
Zai Lab had revenue of $116.10M in the quarter ending September 30, 2025, with 13.52% growth. This brings the company's revenue in the last twelve months to $441.63M, up 24.14% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$441.63M
Revenue Growth
+24.14%
P/S Ratio
4.46
Revenue / Employee
$236,292
Employees
1,869
Market Cap
1.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 825.94M |
| Ardelyx | 398.23M |
| Aurinia Pharmaceuticals | 265.81M |
| Vericel | 258.72M |
| Nurix Therapeutics | 83.69M |
| Ocular Therapeutix | 55.78M |
| Nuvation Bio | 26.75M |
| Maze Therapeutics | 2.50M |
ZLAB News
- 12 days ago - Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 20 days ago - Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - Business Wire
- 21 days ago - Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
- 7 weeks ago - Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire
- 7 weeks ago - Zai Lab Announces Updates to China's National Reimbursement Drug List - Business Wire
- 2 months ago - Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) - Seeking Alpha